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Clinical management of drug-resistant tuberculosis patients continues to present signiﬁcant challenges
to global health. To tackle these challenges, the Abbott RealTime MTB RIF/INH Resistance assay was
developed to accelerate the diagnosis of rifampicin and/or isoniazid resistant tuberculosis to within a
day. This article summarizes the performance of the Abbott RealTime MTB RIF/INH Resistance assay;
including reliability, analytical sensitivity, and clinical sensitivity/speciﬁcity as compared to Cepheid
GeneXpert MTB/RIF version 1.0 and Hain MTBDRplus version 2.0. The limit of detection (LOD) of the
Abbott RealTime MTB RIF/INH Resistance assay was determined to be 32 colony forming units/milliliter
(cfu/mL) using the Mycobacterium tuberculosis (MTB) strain H37Rv cell line. For rifampicin resistance
detection, the Abbott RealTime MTB RIF/INH Resistance assay demonstrated statistically equivalent
clinical sensitivity and speciﬁcity as compared to Cepheid GeneXpert MTB/RIF. For isoniazid resistance
detection, the assay demonstrated statistically equivalent clinical sensitivity and speciﬁcity as compared
to Hain MTBDRplus. The performance data presented herein demonstrate that the Abbott RealTime MTB
RIF/INH Resistance assay is a sensitive, robust, and reliable test for realtime simultaneous detection of
ﬁrst line anti-tuberculosis antibiotics rifampicin and isoniazid in patient specimens.
© 2016 The Author. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Drug resistant Mycobacterium tuberculosis is a signiﬁcant issue;
in 2013, there were an estimated 480,000 new cases of multiple
drug resistant TB (MDR-TB), which is deﬁned as MTB with resis-
tance to rifampicin (RIF) and isoniazid (INH), the two most
important ﬁrst-line anti-MTB drugs [1]. For the detection of MDR-
TB, both World Health Organization (WHO) and Centers for Dis-
ease Control and Prevention (CDC) have recommended the use of
rapid nucleic acid ampliﬁcation tests (NAAT) as well as gold stan-
dard culture-based drug sensitivity testing (DST) [2e6].stera), Gregor.Leckie@abbott.
John.Lampinen@abbott.com
Szostak), Klara.B.Abravaya@
. Wang).
td. This is an open access article uThe Abbott RealTime MTB, an assay for the qualitative detection
of MTB in pulmonary specimens (sputum, bronchial alveolar lavage
(BAL), and their N-acetyl-L-cysteine (NALC)-prepared sediment
equivalents) was developed for use on the Abbott m2000 system
[7]. Initial data has been published on theMTB inactivation strategy
and performance of Abbott RealTime MTB [7e9]. The Abbott
RealTime MTB RIF/INH Resistance assay is a companion assay to the
Abbott RealTime MTB assay; it can be executed standalone, or in a
reﬂex mode using the remaining eluents from Abbott RealTime
MTB. The assay is designed to detect RIF and/or INH resistance in
MTB positive samples. This article summarizes the performance of
the Abbott RealTime MTB RIF/INH Resistance assay.2. Materials and methods
The overall workﬂow for the Abbott RealTime MTB RIF/INH
Resistance assay is described in Figure 1.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Abbott RealTime MTB RIF/INH Resistance assay workﬂow. Note: Up to 96
samples (specimens and controls) can be processed using Abbott RealTime MTB and
then reﬂexing test is performed on the MTB positive specimens using Abbott RealTime
MTB RIF/INH Resistance assay (up to 24 samples at a time).
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A sample inactivation procedure is required prior to automated
or manual sample processing. Approximately three volumes of
inactivation reagent (IR) [in 500mL of IR: 20mL 10MNaOH, 300mL
isopropanol, 0.9 mL Tween-20, 179.1 mL Molecular Biology Grade
water] are added to each volume of sample (unprocessed sputum or
BAL, or re-suspended NALC-prepared sediment of sputum or BAL)
[9]. The sample inactivation procedure should occur in a class II
biological safety cabinet. The sample/IR mixture is vortexed twice
for 20e30 s during the ﬁrst hour of incubation. The validated in-
cubation time for the sample mixture is between 1 and 48 h. Once
the sample inactivation process is completed, the samples are
removed from the biological safety cabinet for sample preparation.
2.2. Sample preparation
The Abbott m2000sp instrument is used for automated sample
processing. Prior to initiating an automated sample extraction pro-
tocol on the instrument, an internal control (IC) is added to a sample
preparation reagent that is placed onto them2000sp. A minimum of
0.80 mL of IR-treated sample and assay controls are loaded on an
m2000sp where DNA is isolated from samples using guanidinium
thiocyanate magnetic microparticle technology to capture nucleic
acids. Unbound sample and cellular components are removed from
the DNA bound microparticles through a series of wash steps. After
the wash steps are completed, the nucleic acids bound to the mi-
croparticles are eluted and the 250 ml of eluent are transferred to a
96 deep well plate. The m2000sp instrument is used to create three
different ampliﬁcation mastermixes A, B, and C. Each mastermix
contains AmpliTaq Gold Polymerase, a magnesium chloride activa-
tion reagent, and oligonucleotide reagent (A, B, C) containing
primers, probes, and dNTPs. Them2000spmixes and dispenses 25 ml
aliquots of mastermixes A, B, and C, followed by 25 ml of the
extracted sample eluates to each mastermix in a 96 well optical
reaction plate. The plate is manually sealed with an optical adhesive
ﬁlm and transferred to an Abbott m2000rt for realtime PCR. As an
alternative to the automated m2000sp, sample preparation, mas-
termix preparation, and PCR plate setup can be performedmanually.
2.3. Ampliﬁcation and detection
The Abbott m2000rt instrument is used for ampliﬁcation and
realtime ﬂuorescence detection. Three separate PCR reactions A, B,
and C are performed per sample. To detect the IC, each reactioncontains a primer pair and labeled probe. Reactions A andB contain a
primer pair to produce amplicons for detecting the 81 base pair long
RIF resistance determining region (RRDR) of rpoB using eight
differentdye-labeledprobes (Probes1e4 in reactionA;Probes5e8 in
reaction B) [10,11]. Each RRDR probe is designed to hybridize to a RIF
drug sensitive sequence of MTB. Mutation(s) in the RRDR would
prevent complete hybridization of the rpoBwild type probe(s) in the
respective region, generating an assay result of “rpoB Pbc-,”with an
assay interpretation of “RIF R det,” RIF resistance detected.
Conversely, for a sample where all 8 rpoB probes are detected, an
assay result of “rpoBwt”would accompanyan assay interpretation of
“RIF R-,” RIF resistance not detected. Reaction C contains two primer
pairs to produce amplicons for detecting INH resistance: one primer
pair targeting the katG gene and the second primer pair targeting the
inhA Upper Strand Promoter (USP) region [10,11]. There are four
labeled probes in reaction C: a labeled probe to detect katGwild type
sequence, a labeled probe to detect the katG S315T1 drug resistance
mutation commonly associated with high level INH resistance, a
labeled probe to detect inhA USP wild type sequence, and a labeled
probe to detect the inhA C-15T mutation commonly associated with
low level INHresistance [12]. Forexample, a sample containinga katG
315T1 mutation, will be detected by the assay katG 315T1 mutation
speciﬁc probe with assay result of “katG 315T1” and assay interpre-
tation of “INHHighR.”Additionally, a sample containing an inhA -15T
mutation, will be detected by the assay inhA -15T mutation speciﬁc
probe with assay result of “inhA -15T” and assay interpretation of
“INH Low R.” Furthermore, for a sample that contains a mutation
other than katG 315T1, ie katG 315N, with no mutation in inhA USP
probe binding region, the assay katG wild type probe and mutation
315T1 probe signal will not be detected, but the inhAwild type probe
signal would be detected, generating an assay result of “katG-, inhA
wt;”with an assay interpretation of “INH R*,” INH resistance may be
indicated. Also, for a sample that contains amutation other than inhA
-15T, ie inhA -8A, with nomutation in the katG probe binding region,
the assay katGwild type probe signalwould be detected, but the inhA
wild type probe and -15T mutation probe signal would not be
detected, generatinganassay resultof “katGwt, inhA-;”withanassay
interpretation of “INH R*,” INH resistance may be indicated. In the
eventwhereonlyoneof thePCR reactionworked, inotherwords, two
out of the three PCR reactions failed for a given sample, the assay
would returna “BelowLOD” interpretationwithassay resultof “rpoB-
” if both rpoB reactions (reactions A and B) are not detected or with
assay result of “rpoB Indeterminate” if one rpoB reaction is detected;
the assay would also return a “Below LOD” interpretationwith assay
result of “katG-, inhA-” if INH reaction (reactions C) is not detected.
Figure 2a and b include the overall arrangement of the assay
probes.
2.4. Assay controls
A minimum of one replicate of the Negative Control and one
replicate of the Positive Control are used to determine run validity.
The positive control consists of plasmid DNA containing ﬁve DNA
sequencesof three target regions (rpoBRRDRwildtype,katGwildtype,
inhA USP wildtype, katG S315T1 mutation, and inhA C-15T USP mu-
tation). The IC is formulated with a synthetic DNA construct con-
taining a pumpkin hydroxypyruvate reductase (HPR) sequence and is
added prior to sample preparation, serving as a control for sample
preparation recovery, sample inhibition, and ampliﬁcation efﬁciency.
2.5. Optional reﬂex testing
The Abbott RealTime MTB RIF/INH Resistance assay can be
performed in standalone mode starting with sample inactivation/
preparation and going through ampliﬁcation and detection, or it
Figure 2. a: Design of Abbott RealTime RIF/INH Resistance rpoB Probes. b: Design of Abbott RealTime RIF/INH Resistance INH Probes.
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mode, the Abbott RealTime MTB RIF/INH Resistance uses remaining
eluents from Abbott RealTime MTB. Samples identiﬁed as “MTB
detected” by Abbott RealTime MTB can be reﬂex tested using
Abbott RealTime MTB RIF/INH Resistance. For samples to be reﬂex
tested, the Abbott RealTime MTB RIF/INH Resistance Positive Con-
trol must have been processed through sample preparation,
alongside the controls for Abbott RealTime MTB.
2.6. Panels and clinical specimens
2.6.1. MTB complex subspecies and samples with identiﬁed drug
resistant mutations and heteroresistance
Twenty MTB complex DNAs were tested including Mycobacte-
rium africanum 25420, M. africanum 35711, Mycobacterium bovis
35735, M. bovis 19274, M. bovis BCG 35746, M. bovis BCG 35747D,
Mycobacterium canettii, Mycobacterium caprae BAA-824D, Myco-
bacteriummicroti 11152,M.microti 19422,Mycobacterium pinnipedii
BAA-688D, MTB 25177D-5 (H37Ra), MTB 25618D-5 (H37Rv), MTB
BAA-2236D, MTB BAA-2237D, MTB 27294D, MTB BAA-2234D, MTB
35822D, MTB 35838D, MTB BAA-2235D [13]. Nineteen of these
DNA samples were obtained from the American Type Culture
Collection (ATCC, Manassas, VA) while one (Mycobacterium canettii)
was provided by Ibis Biosciences (Carlsbad, CA). The DNA concen-
trations of the samples were determined using the PicoGreen®
NanoDropmethod with the exception of three samples where such
measurements could not be obtained. These three samples were
diluted at a sample to water ratio of 1:600 and tested directly.
Heteroresistance detection was studied using MTB wild type and
mutation panel members that included major mutations rpoB
S531L (TCG-TTG), katG S315T1 (AGC-ACC), and inhA C-15T.
2.6.2. Limit of detection (LOD)
A RIF/INH drug sensitive MTB H37Rv panel targeted to
1  105 cfu/mL was prepared by Zeptometrix (Buffalo, NY). Three
one mL aliquots of the Zeptometrix panel were combined and
centrifuged at 3000 g for 15 min to remove free MTB DNA in the
supernatant. The cell pellet was re-suspended in TE buffer and then
added to a pool of homogenized MTB-negative sputum, obtained
from Northwestern University Memorial Hospital (Chicago, IL), to
make the following diluted MTB panel-members: 80 cfu/mL,
50 cfu/mL, 25 cfu/mL, 10 cfu/mL, 5 cfu/mL, 1 cfu/mL, 0.5 cfu/mL, and
0.1 cfu/mL. The same LOD panel members were used to test the LOD
performance of Abbott RealTime MTB [7].
2.6.3. Analytical speciﬁcity
Analytical speciﬁcity panel members (n ¼ 80) were collected as
follows: 69 mycobacterial and other microorganism species wereobtained from ATCC, eight bacterial isolates were cultured at
Abbott Molecular, and Cytomegalovirus, Herpes Simplex virus 1,
and Varicella-zoster virus were obtained from Advanced Biotech-
nology Inc. (Columbia, MD).
2.6.4. Potentially interfering substances
The following materials were tested: blood, DNA from human
cells, gastric acid, hypertonic saline, physiologic saline, culturemedia,
NALC pelletmaterial, ﬁve anti-TBmedications (Isoniazid, Rifampicin,
Streptomycin, Pyrazinamide, Ethambutol), and bovine mucus.
2.6.5. Carryover
Carryover studies were performed using drug sensitive MTB and
drug resistant MTB mutant plasmid panel members.
2.6.6. Reproducibility
Reproducibility studies were performed using an MTB strain
H37Rv cell line at a concentration less than or equal to three times
the Limit of Detection in pooled MTB negative sputum, and one
MTB negative panel member in pooled MTB negative sputum MTB
negative sputum was obtained from Northwestern University Me-
morial Hospital (Chicago, IL).
2.6.7. Clinical specimens
MTB positive specimens (unknown HIV status) were collected
from patients in Russia and Bangladesh by Discovery Life Sciences
(Los Osos, CA) and Sage Bio Networks Ltd. (Dhaka, Bangladesh) at the
National TB Reference Lab. All patient specimens were collected un-
der collection countries National TB Reference Lab Institutional Re-
view Board (IRB) and Intercenter Agreement (ICA). Samples were
consecutively collected and stored at 20C for approximately 6
monthsuntil tested. Forall specimens smear, culture, andcomparator
testingwasperformednear the collection site,whileAbbott RealTime
MTB RIF/INH Resistance assay testing was performed at Abbott Mo-
lecular. For discrepant results/interpretations between Abbott Real-
TimeMTBRIF/INHResistance andDST, bi-directional sequencingwas
performed for the respective PCR products from reactions A, B, and C
by Abbott Diagnostic Division using Life Technology BigDye 3.1 and
POP-7 and Applied Biosystems 3130xL DNA Sequencer/Analyzer.
3. Results
3.1. MTB complex subspecies detection and detection of resistance
mutations and heteroresistance
Each of 20 different puriﬁed DNAs representing eight different
species (M. africanum, M. bovis, M. bovis BCG, M. canettii, M. caprae,
M. microti, M. pinnipedii, and M. tuberculosis) of the MTB complex
Table 1
Abbott RealTime MTB RIF/INH Resistance LOD study in sputum.
MTB target
concentration CFU/ml
Number
tested
Number
detected
Percent
detected
80 19* 19 100%
50 20 19 95%
25 20 20 100%
10 20 16 80%
5 20 4 20%
1 20 3 15%
0.5 20 0 0%
* One replicate of the 80 CFU/mL Panel Member was excluded from the data
analysis due to an Internal Control invalid result.
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from the 20 MTB complex species were detected by Abbott Real-
Time MTB RIF/INH Resistance (i.e gave assay interpretations). 18 of
20 strains tested had assay results (rpoB wt, katG wt, inhA wt) and
interpretations of RIF and INH drug sensitive (RIF R-; INH R-). A
“rpoB wt,” “katG wt,” or “inhA wt” assay result correlates to
detectable signal from the respective assay reaction wild type
probes, corresponding to a respective drug sensitive assay inter-
pretation. StrainsM. bovis BCG 35747D and MTB 35822D had assay
results (rpoB wt, katG-, inhA wt) and interpretations of RIF drug
sensitive and possible INH resistance (RIF R-; INH R*). For these
samples where all 8 rpoB probes are detected, an assay result of
“rpoB wt”would accompany an assay interpretation of “RIF R-,” RIF
resistance not detected. A “katG-” result correlates to the absence of
detectable signal from both katG wildtype probe and 315T1 mu-
tation probe (may indicate presence of non-315T1 mutation or
deletion). A “inhAwt” assay result correlates to no mutation in inhA
USP probe binding region, therefor the inhAwild type probe signal
would be detected resulting in an assay interpretation of “RIF R-;
INH R*.” Both strains (ATCC 35747D and ATCC 35822D) have
conﬁrmed katG deletions supporting the correct assay results and
interpretations [14,15]. Additional MTB panel sets consisting of wild
type panel member and resistance panel members covering major
resistance mutations (rpoB 531L, 526Y, 516V, 511P; katG 315T1,
315T2, 315N, 315I; inhA USP -15T, -8A, -8C, -17T) were tested,
generating correct Abbott RealTime MTB RIF/INH Resistance results
and interpretations (data not shown). Heteroresistant mutation
detection by the Abbott RealTime MTB RIF/INH Resistance assay
was studied with mixed panels using a wild type panel and a
mutation panel. The mutation panel included major mutations
rpoB S531L (TCG-TTG), katG S315T1 (AGC-ACC), and inhA C-15T.
The following mixed panel testing scheme was used: 100%WT:0%
MT (1.0E5copies/ml:0copies/ml), 90%WT:10%MT (9.0E4copies/
ml:1.0E4copies/ml), 70%WT:30%MT (7.0E4copies/ml:3.0E4copies/
ml), 50%WT:50%MT (5.0E4copies/ml:5.0E4copies/ml), 30%WT:70%
MT (3.0E4copies/ml:7.0copies/ml), 10%WT:90%MT (1.0E4copies/
ml:9.0E4copies/ml), and 0%WT:100%MT (0copies/ml:1.0E5copies/
ml). The results of this study demonstrated that a sample must
contain at least a 70%mutation composition for the mutations to be
detected with the correct Abbott RealTime MTB RIF/INH Resistance
assay result (rpob Pb4-, katG 315T1, inhA-15T) and the correct
interpretation (RIF R det; INH High R).
3.2. Limit of detection (LOD)
20 replicates of each panel member (80 cfu/mL, 50 cfu/mL,
25 cfu/mL, 10 cfu/mL, 5 cfu/mL, 1 cfu/mL, 0.5 cfu/mL, and 0.1 cfu/
mL) were tested across eight assay runs. The study was conducted
using one lot of Abbott RealTime MTB RIF/INH Resistance assay and
control reagents on two instrument systems. A samplewas counted
as detected if the correct result and interpretation was produced.
The detection rate was calculated for each target concentration
(Table 1). A Probit analysis of the data determined that the con-
centration of MTB detected with 95% probability was 32 cfu/mL
(95% CI 16e183 cfu/mL). The claimed LOD of the Abbott RealTime
MTB RIF/INH Resistance assay is 60 cfu/mL in pooled homogenized
MTB negative sputum using the MTB H37Rv strain.
3.3. Analytical speciﬁcity
Each of the 80 potential cross-reactants was tested in both a
MTB drug resistant sample and a MTB drug sensitive sample.
Nucleic acid from cultured microorganisms at a target concentra-
tion of 1  106 cfu/mL or puriﬁed nucleic acid from each microor-
ganism or virus at a targeted concentration of 1  105 to 1  107copies or genomes/mL were added to samples that contained
1000 cfu/mL MTB RIF/INH drug resistant cells (rpoB S531L, katG
S315T1, inhA wt) or 1000 cfu/mL MTB RIF/INH drug sensitive cells
(rpoB wt, katG wt, inhA wt). All samples gave the expected assay
results and interpretations (“rpoB Pb4-, katG 315T1, inhAwt” result
with “RIF R det; INH High R” interpretation for RIF/INH drug
resistant cells or “rpoB wt, katG wt, inhAwt” result and “RIF R-; INH
R-” interpretation for RIF/INH drug sensitive cells) when tested in
the presence of potential cross-reactors (Table 2).
3.4. Potentially interfering substances
Performance susceptibility of the Abbott RealTime MTB RIF/INH
Resistance assay to interfering substances found in respiratory
specimens (mucus, blood, DNA from human cells, gastric acid, hy-
pertonic saline, physiological saline, culture media, NALC pellet
material and ﬁve anti-TB medications [Isoniazid, Rifampicin,
Streptomycin, Pyrazinamide, Ethambutol]) were evaluated. All
samples, 1000 cfu/mL (12.5 cfu/25 ml eluate in 50 ml PCR reaction)
MTB RIF/INH drug resistant cells (rpoB S531L, katG S315T1, inhAwt)
and 1000 cfu/mL (12.5 cfu/25 ml eluate in 50 ml PCR reaction) MTB
RIF/INH drug sensitive cells (rpoB wt, katG wt, inhA wt), gave the
expected assay results and interpretations (“rpoB Pb4-, katG 315T1,
inhA wt” result with “RIF R det; INH High R” interpretation for RIF/
INH drug resistant cells or “rpoB wt, katG wt, inhA wt” result and
“RIF R-; INH R-” for RIF/INH drug sensitive cells) when tested in the
presence of potential cross-reactors (Table 3).
3.5. Carryover
Potential sample carryover within the Abbott RealTimeMTB RIF/
INH Resistance assay was evaluated by testing ﬁve runs consisting
of 55 high concentration (1 107 copies/mL) RIF/INH drug sensitive
MTB wild type plasmid samples interspersed with 55 low con-
centration (1  104 copies/mL) RIF/INH drug resistant MTB mutant
plasmid samples and ﬁve runs consisting of 55 high concentration
(1  107 copies/mL) RIF/INH drug resistant MTB mutant plasmid
samples interspersed with 55 low concentration (1  104 copies/
mL) RIF/INH drug sensitive MTB wild type plasmid samples. All
samples, MTB RIF/INHwild type plasmid samples (rpoBwt, katGwt,
inhA wt) and MTB RIF/INH mutant plasmid samples (rpoB S531L,
katG S315T1, inhA C-15T), gave the expected assay results and in-
terpretations (“rpoBwt, katGwt, inhAwt” result and “RIF R-; INH R-
” for wild type plasmid samples or “rpoB Pb4-, katG 315T1, inhA
-15T” result with “RIF R det; INH High R” for drug resistant MTB
mutant plasmid samples), with no detectable carryover from high
concentration samples to low concentration samples.
3.6. Reproducibility
The reproducibility of Abbott RealTime MTB RIF/INH Resistance
was evaluated by testing a panel consisting of one positive panel
Table 2
Potential cross reactors tested.
Mycobacteriumabscessus Campylobacter jejuni
Mycobacteriumasiaticum Candida albicans
Mycobacteriumaustroafricanum Chromobacterium violaceum
Mycobacteriumavium Chlamydia pneumoniae
Mycobacteriumavium ssp. Avium Chlamydia trachomatis
Mycobacterium avium ssp. paratuberculosis Citrobacter freundii
Mycobacteriumcelatum Corynebacterium diptheriae
Mycobacteriumchelonae Corynebacterium xerosis
Mycobacteriumchitae Cryptococcus neoformans
Mycobacteriumfallax Cytomegalovirus
Mycobacteriumﬂavescens Enterobacter aerogenes
Mycobacteriumfortuitum Enterobacter cloacae
Mycobacteriumgastri Enterococcus faecalis
Mycobacteriumgordonae Enterococcus avium
Mycobacteriumintracellulare Escherichia coli
Mycobacteriumkansasii Haemophilus inﬂuenzae
Mycobacteriumlentiﬂavum Herpes simplex virus 1
Mycobacteriummarinum Klebsiella pneumoniae
Mycobacteriumneoaurum Lactobacillus delbrueckii
Mycobacteriumnonchromogenicum Legionella pneumophila
Mycobacteriumphlei Neisseria gonorrhoeae
Mycobacteriumpneumoniae Neisseria meningitidis
Mycobacteriumpulveris Porphyromonas gingivalis
Mycobacteriumscrofulaceum Proteus mirabilis
Mycobacterium shimoidei Pseudomonas aeruginosa
Mycobacteriumsimiae Salmonella choleraesuis
Mycobacteriumsmegmatis Serratia marcescens
Mycobacteriumsphagni Staphylococcus aureus
Mycobacteriumszulgai Staphylococcus epidermidis
Mycobacteriumterrae Staphylococcus haemolyticus
Mycobacteriumthermoresistibile Staphylococcus hominis
Mycobacteriumtokaiense Streptococcus agalactiae
Mycobacteriumulcerans Streptococcus gordonae
Mycobacteriumvaccae Streptococcus mitis
Mycobacteriumxenopi Streptococcus mutans
Acinetobacter baumannii Streptococcus pneumoniae
Aeromonas hydrophila Streptococcus pyogenes
Bacillus cereus Streptomyces griseinus
Bacillus subtilis Varicella-zoster virus
Bordetella parapertussis Veillonella parvula
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times the assay LOD in pooled culture negative sputum, and one
MTB-negative panel member in pooled culture negative sputum.
The panels were tested by four operators using two lots of Abbott
RealTime MTB RIF/INH Resistance ampliﬁcation reagents and two
lots of control reagents: two operators performing runs using an
Abbott m2000sp instrument and two operators performing runs
using manual sample preparation. For each sample preparation
method, the two operators each used one unique lot of Abbott
RealTime MTB RIF/INH Resistance ampliﬁcation reagents/control
reagents and tested each panel member in replicates of eight, once
per day, for ﬁve days, for a total of 40 replicates per panel member
(80 total replicates per panel member per method; 160 total tested
with m2000sp instrument sample preparation and 160 total tested
with manual sample preparation). Samples were counted as
correctly identiﬁed if both the correct results and interpretations
were produced (“rpoB wt, katG wt, inhAwt” result and “RIF R-; INH
R-” interpretation as RIF/INH drug sensitive for MTB positive panel
member (MTB H37Rv), or “rpoB-; katG-; inhA-” result and “Below
LOD” interpretation for MTB negative panel member). For the
automated m2000sp sample preparation method, the Abbott
RealTime MTB RIF/INH Resistance assay produced 99.4% (159/160)
correct results and interpretations with a 95% CI of (96.6e99.9). For
the manual sample preparation method, Abbott RealTime MTB RIF/
INH Resistance with expected results was 98.1% (156/159) with a
95% CI of (94.6e99.6) for samples prepared manually.3.7. Clinical sensitivity and speciﬁcity
Clinical performance characteristics of the Abbott RealTimeMTB
RIF/INH Resistance assay were evaluated by testing MTB positive
patient specimens from non-US populations. Acid-Fast Bacilli (AFB)
smear testing was performed for all patient specimens. MTB sus-
pect patient specimens, AFB smear positive or negative, were
processed by NALC 2% NaOH method prior to culture using
Lowenstein-Jensen medium. RIF and INH susceptibility test (DST)
was performed on culture positive patient specimens. RIF and INH
susceptibility was determined by solid Lowenstein-Jensen medium
drug susceptibility tests using proportion method with rifampicin
concentration of 40.0 mcg/ml and isoniazid concentration of
0.2 mcg/ml. RIF results were obtained for Abbott and Cepheid
GeneXpert MTB/RIF for 216 (40 AFB smear negative or scanty/176
AFB smear positive), culture positive specimens with DST infor-
mation. All testing between Cepheid GeneXpert MTB/RIF version
1.0 and Abbott RealTime MTB RIF/INH Resistance was blinded and
decoded. Bi-directional DNA sequencing was performed for clinical
specimens with discrepant results/interpretations between Abbott
RealTime MTB RIF/INH Resistance and DST. The Abbott RealTime
MTB RIF/INH Resistance assay demonstrated a RIF sensitivity of
94.8% (91/96), with 95% CI (88.3e98.3%) and a RIF speciﬁcity of
100% (120/120), with 95% CI (97.0e100%). The rpoB amplicons of
the ﬁve samples with negative Abbott RealTime MTB RIF/INH
Resistance assay RIF results vs. DST were analyzed using bi-
directional DNA sequencing; four of the samples did not contain
any mutations in the rpoB amplicon probe-binding region, while
one sample contained a mutation S531L (TCG to TTG) in rpoB
amplicon probe-binding region that Abbott RealTime MTB RIF/INH
Resistance assay failed to detect. In the same sample population,
the Cepheid GeneXpert demonstrated a RIF sensitivity of 95.8% (92/
96) with 95% CI (89.7e98.9%) and a RIF speciﬁcity of 100% (120/120)
with 95% CI (97.0e100%).
INH results were obtained for Abbott and Hain MTBDRplus for
220 (41 AFB smear negative or scanty/179 AFB smear positive),
culture positive specimens with DST information. All testing be-
tween Hain MTBDRplus version 2.0 and Abbott RealTime MTB RIF/
INH Resistance was blinded and decoded. Three MTB INH drug
sensitive samples by DST were reported as MTB INH drug resistant
by both Abbott RealTime MTB RIF/INH Resistance and the Hain
MTBDRplus comparator and therefore not included in the analysis
because bi-directional sequencing results conﬁrmed presence of
mutation in target regions (two samples contained katG 315T1
mutation and one sample contained inhA -15T mutation). The
Abbott RealTime MTB RIF/INH Resistance assay demonstrated an
INH sensitivity of 88.3% (83/94) with 95% CI (80.0e94.0%) and an
INH speciﬁcity of 94.3% (116/123) with 95% CI (88.6e97.7%). By bi-
directional sequencing, ten of the eleven samples with negative
Abbott RealTime MTB RIF/INH Resistance assay INH results, but
positive by DST, were conﬁrmed to be wild type in the katG and
inhA USP target regions. One sample contained a S315T1 mutation
(AGC to ACC) in the katG assay probe binding region that Abbott
RealTime MTB RIF/INH Resistance assay failed to detect. By bi-
directional sequencing, seven samples with positive Abbott Real-
TimeMTB RIF/INH Resistance assay INH results, but negative by DST
contained a mutation in the katG or inhA USP assay probe binding
region (three contained katG S315T1 (AGC to ACC) mutation, four
contained inhA USP -15 C to T mutation). In the same sample
population, the Hain MTBDRplus assay demonstrated an INH
sensitivity of 87.2% (82/94) with 95% CI (78.8e93.2%) and a speci-
ﬁcity of 96.7% (119/123) with 95% CI (91.9e99.1%).
Clinical sensitivity and speciﬁcity results are presented in
Tables 4 and 5.
Table 4
Abbott RealTime MTB RIF/INH Resistance RIF clinical sensitivity and speciﬁcity.
Drug susceptibility (DST)
RIF resistant RIF sensitive
Abbott RealTime MTB RIF/INH Resistance RIF Resistance Detected 91 0
RIF Resistance Not Detected 5* 120
N ¼ 216, Sensitivity 94.8% (91/96), Speciﬁcity 100% (120/120).
Note: In the same sample population, a RIF comparator assay demonstrated a RIF sensitivity of 95.8% ([92/96], [95% CI 89.7e98.9%]) and a RIF speciﬁcity of 100% ([120/120],
[95% CI 97.0e100%]).
* By sequencing of the assay amplicons, four samples were wild type and were corroborated by bi-directional sequencing. One sample contained a mutation in the assay
probe binding region.
Table 3
Potential interfering substances tested.
Potentially interfering substance Specimen source Concentration/percentage
Mucus Sputum Mucin 5% (w/v)
Blood Sputum or BAL 5% (v/v)
DNA from human cells Sputum, BAL, NALC 1  106 cells/mL
Gastric acid Sputum/BAL pH 3e4 HCl in water, neutralized to
pH 6.8 with sodium bicarbonate
Hypertonic saline used to induce sputum Sputum NaCl (5% w/v)
Physiologic saline used to collect BAL BAL NaCl (0.9% w/v)
Culture media MTB culture 100%
Material used to re-suspend NALC pellets NALC pellets 0.067 M phosphate, pH 6.8
Isoniazid (anti-TB medication) Sputum or BAL 90 mg/mL
Rifampicin/rifampin (anti-TB medication) Sputum or BAL 120 mg/mL
Streptomycin (Anti-TB medication) Sputum or BAL 400 mg/mL
Pyrazinamide (anti-TB medication) Sputum or BAL 500 mg/mL
Ethambutol (anti-TB medication) Sputum or BAL 60 mg/mL
Table 5
Abbott RealTime MTB RIF/INH Resistance INH clinical sensitivity and speciﬁcity.
Drug susceptibility (DST)
INH resistant INH sensitive
Abbott RealTime MTB RIF/INH Resistance INH Resistance Detected 83 7y
INH Resistance Not Detected 11* 116
N ¼ 217, Sensitivity 88.3% (83/94), Speciﬁcity 94.3% (116/123).
Note: In the same sample population, an INH comparator assay demonstrated an INH sensitivity of 87.2% ([82/94], [95% CI 78.8e93.2%]) and a speciﬁcity of 96.7% ([119/123],
[95% CI 91.9e99.1%]).
* Per sequencing of the amplicons, ten samples were wild type and were corroborated by bi-directional sequencing. One sample contained a mutation in the assay probe
binding region.
y Per sequencing of the assay amplicons, seven samples contained a mutation in the assay probe binding region that was corroborated by bi-directional sequencing.
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The Abbott RealTimeMTB RIF/INH Resistance assay was designed
as a standalone assay to detect RIF and INH resistant MTB with the
additional capability to reﬂex test MTB positive specimens by Abbott
RealTime MTB [7e9]. The Abbott RealTime RIF/INH Resistance assay
uses the same sample inactivation and sample preparation protocols
as Abbott RealTime MTB to test sputum, BAL, and NALC sediments of
sputum and BAL. In the reﬂex mode, sample eluents with an assay
interpretation of “MTB detected” using Abbott RealTimeMTB, can be
reﬂex-tested using Abbott RealTime MTB RIF/INH Resistance. The
reﬂex-testing can be performed using a manual PCR plate set-up, or
automatedm2000sp PCR plate set-up. A workﬂow advantage of the
reﬂex mode is that only samples positive by Abbott RealTime MTB
need to be tested by Abbott RealTime RIF/INH Resistance, thus
reducing assay test time as well as cost.
Abbott RealTime MTB RIF/INH Resistance uses 8 target probes to
detect the 81 base pair RRDR region of rpoB associated with~95e98% of RIF resistance, uses 4 target probes to detect the katG
and inhA USP regions associated with ~70e84% of INH drug resis-
tance [10,11]. Abbott RealTime MTB RIF/INH Resistance, like
Cepheid GeneXpert and HainMTBDRplus, will not detect mutations
out of the assay amplicon regions (e.g., rare rpoB mutations V146F
and I572F, which are outside the 81 bp RRDR) [18].
This study assessed the reliability, analytical sensitivity, and
clinical sensitivity and speciﬁcity of the Abbott RealTime MTB RIF/
INH Resistance assay. Reliability was assessed by conﬁrming that
the assay detected 20 DNAs representative of the most common
sub-species of the MTB complex [13], by demonstrating that the
assay did not cross-react with 80 potentially cross-reactive micro-
organisms, by producing correct results when challenged with
potentially interfering substances and by no-detectable carryover
from a high positive drug resistant sample to a low positive drug
sensitive sample, or vice-versa. The analytical sensitivity of the
assay was evaluated by testing MTB strain H37Rv. The study
demonstrated that the analytical sensitivity of Abbott RealTime
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mL. The analytical sensitivity of Abbott RealTime MTB was 2.45 cfu/
mL with a label claim of 17 cfu/mL using the same panel [7]. The
higher sensitivity of Abbott RealTime MTB as compared to Abbott
RealTime MTB RIF/INH Resistance is because Abbott RealTime MTB
targets IS6110, which is present in multiple copies per genome of
MTB as compared to the targets (RRDR of rpoB, katG, inhA) of Abbott
RealTime RIF/INH Resistance that are single copy per genome
[16,17].
The clinical sensitivity and speciﬁcity of the Abbott RealTime
MTB RIF/INH Resistance assay was assessed by comparing it to
DST information for all patient specimens. DST was selected as
the comparator since it is continues to be considered the gold
standard for identifying drug resistance patterns in patient
specimens [2e6]. Furthermore, the interpretations and results
from the Hain and Cepheid assays were also compared to DST for
patient specimens. Sequencing of the rpoB, katG, and inhA USP
target regions was performed for samples with discrepant result
between the Abbott RealTime MTB RIF/INH Resistance assay,
Cepheid GeneXpert, Hain MTBDRplus, and DST. The Abbott Real-
Time MTB RIF/INH Resistance assay had statistically equivalent
sensitivity and speciﬁcity compared to Cepheid GeneXpert for
detection of RIF resistance. Detecting both RIF and INH Resistance
simultaneously, the Abbott RealTime MTB RIF/INH Resistance
assay has an advantage over Cepheid GeneXpert MTB/RIF that
fails to detect INH mono-resistance, often linked to poor treat-
ment outcome in RIF-susceptible but INH-resistant patients
[19e21]. Additionally, the Abbott RealTime MTB RIF/INH Resis-
tance assay demonstrated statistically equivalent sensitivity and
speciﬁcity as compared to Hain MTBDRplus for INH resistance
detection.
The Abbott RealTime MTB RIF/INH Resistance is performed us-
ing the m2000™ system analyzer, a system that is capable of
running multiple assays including Abbott RealTime HIV, thus
enabling efﬁcient management of MTB-HIV co-infected patients.
Additionally, the assay delivers an automated solution to simulta-
neously diagnosis rifampicin and/or isoniazid resistant MTB with
statistically equivalent sensitivity and speciﬁcity as compared to
Cepheid GeneXpert MTB/RIF and Hain MTBDRplus. The Abbott
RealTime MTB RIF/INH Resistance assay will provide many beneﬁts
for patients worldwide, including rapid diagnosis to administer
appropriate efﬁcacious treatment quickly, deterring the trans-
mission of drug resistant MTB.Acknowledgements
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